Generic Durysta Availability
Last updated on Apr 10, 2025.
Durysta is a brand name of bimatoprost ophthalmic, approved by the FDA in the following formulation(s):
DURYSTA (bimatoprost - implant;ophthalmic)
-
Manufacturer: ABBVIE
Approval date: March 4, 2020
Strength(s): 10MCG [RLD]
Is there a generic version of Durysta available?
No. There is currently no therapeutically equivalent version of Durysta available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Durysta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Processes for making cyclic lipid implants for intraocular use
Patent 10,441,543
Issued: October 15, 2019
Inventor(s): Spada Lon T. & Chang James N. & Luu Michelle H.
Assignee(s): Allergan, Inc.Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.
Patent expiration dates:
- December 19, 2026✓
- December 19, 2026
-
Hypotensive lipid-containing biodegradable intraocular implants and related methods
Patent 7,799,336
Issued: September 21, 2010
Inventor(s): Hughes; Patrick M.
Assignee(s): Allergan, Inc. (Irvine, CA)Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
Patent expiration dates:
- April 24, 2029✓
- April 24, 2029
-
Hypotensive lipid-containing biodegradable intraocular implants and related methods
Patent 8,206,737
Issued: June 26, 2012
Inventor(s): Hughes Patrick M.
Assignee(s): Allergan, Inc.Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
Patent expiration dates:
- April 7, 2027✓
- April 7, 2027
-
7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
Patent 8,629,185
Issued: January 14, 2014
Inventor(s): Ambrus Gyorgy F. & Karami Kiomars & Wu Ke
Assignee(s): Allergan, Inc.The present invention provides a new crystalline form of bimatoprost, designated as crystalline form II. This new crystalline form is the most stable form known to date of bimatoprost. Moreover, it has been found that bimatoprost crystalline form II is readily prepared from crystalline form I.
Patent expiration dates:
- July 15, 2031✓✓
- July 15, 2031
-
Intraocular pressure reduction with intracameral bimatoprost implants
Patent 8,673,341
Issued: March 18, 2014
Inventor(s): Hughes Patrick M.
Assignee(s): Allergan, Inc.The present invention provides a method of treating an ocular condition in an eye of a patient, comprising the step of placing a biodegradable intraocular implant in an eye of the patient, the implant comprising a prostamide and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the prostamide from the implant to provide an amount of the prostamide effective to prevent or reduce a symptom of an ocular condition of the eye, wherein said ocular condition is elevated IOP and said implant is placed in an intracameral location to dilate the outflow channels of the eye emanating from Schlemm's Canal.
Patent expiration dates:
- February 19, 2025✓
- February 19, 2025
-
Processes for making cyclic lipid implants for intraocular use
Patent 9,149,428
Issued: October 6, 2015
Inventor(s): Spada Lon T. & Chang James N. & Luu Michelle H.
Assignee(s): Allergan, Inc.Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.
Patent expiration dates:
- December 19, 2026✓
- December 19, 2026
-
Prostamide-containing intraocular implants and methods of use thereof
Patent 9,492,316
Issued: November 15, 2016
Inventor(s): Ghebremeskel Alazar N. & Robinson Michael R.
Assignee(s): Allergan, Inc.Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.
Patent expiration dates:
- October 31, 2034✓
- October 31, 2034
-
Prostamide-containing intraocular implants and methods of use thereof
Patent 9,980,974
Issued: May 29, 2018
Inventor(s): Ghebremeskel Alazar N. & Robinson Michael R.
Assignee(s): Allergan, Inc.Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.
Patent expiration dates:
- October 31, 2034✓
- October 31, 2034
More about Durysta (bimatoprost ophthalmic)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: ophthalmic glaucoma agents
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.